

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810

Status RECRUITING
Sponsor AstraZeneca
Enrollment 1,850 participants

Key Eligibility Criteria

Inclusion (4)

- Patient willing and able to provide written informed consent to participate in the study
- Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
- Aged ≥18 years at the time of signing the informed consent
- Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

Exclusion (4)

- Concurrent participation in any interventional trial for ATTR amyloidosis
- Involvement in the planning and/or conduct of the current study
- Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
- Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers

Locations (53 total)

Research Site, La Jolla, California, United States
Research Site, Los Angeles, California, United States
Research Site, San Francisco, California, United States
... and 50 more locations